Inherited genetic variants in tumour suppressors and oncogenes can increase the cancer risk, but little is known about their influence on anthropometric traits. Through the integration of inherited and somatic cancer genetic data, we define functional single nucleotide polymorphisms (SNPs) associated with cancer risk and explore potential pleiotropic associations with anthropometic traits in a cohort of 500,000 individuals. We identify three regulatory SNPs for three important cancer genes that associate with both anthropometric traits and cancer risk. We describe a novel association of a SNP in TP53 (rs78378222) with height, lean body mass measures and basal metabolic rate, as well as validating its known associations with brain and non-melanomatous skin cancer susceptibility. Our results clearly demonstrate that heritable variants in key cancer genes can associate with both differential cancer risk and anthropometric traits in the general population, thereby lending support for a role of genetics in linking these human phenotypes.
Introduction
Height and other anthropometric measures have been consistently found to associate with differential cancer risk 1, 2, 3 . However, both genetic and mechanistic insights into these epidemiological associations are notably lacking 2, 4 . Increased height has been seen to associate with a number of malignancies including skin, breast colon, rectum, endometrium, ovary, kidney cancers as well as Hodgkin's lymphoma and leukaemia 2, 5, 6 . Current theories underpinning links between increased height and increased cancer risk centre upon the role of growth hormone, insulin-like growth factor and/or insulin being pro-tumorigenic by upregulating the Ras-MAPK and PI3K pathways leading to increased cellular proliferation 7, 8 . It has also been proposed that increased height might correspond to increased cellular number and therefore increased probability of malignancy, simply by chance 9 ; however, such allometric scaling of body mass only explains part of the observed effect and it is not observed among mammal species of different size (Peto's paradox) 10 . Like height, increased body mass index (BMI), a surrogate measure of obesity based on height and weight, has been associated with an increased risk of number of cancers including post-menopausal breast cancer, colorectal cancer and renal cancer 3, 11, 12 . Increased BMI within individuals has been mainly attributed to increasing accumulation of fat mass. It is hypothesised that adiposity causes a state of systemic inflammation, a shift of metabolite and adipokine release, and an increase of circulating insulin, secondary to insulin resistance 13, 14 . This combination may increase cancer risk. However, the exact and predominant mechanisms of how high BMI is linked with increased cancer risk are not understood. Thus, links between height, anthropometric measures and cancer remain an intense area of research.
Anthropometric traits are largely determined by genes that control cellular proliferation, metabolism and apoptosis: these attributes are also required for immortalisation of cancer cells and development of tumours 15, 16 . It is well established that germline mutations within tumour suppressor genes and oncogenes, affect cancer risk 17, 18 ; however, their influence on anthropometric traits is not well-known. From studying mouse models and rare diseases, there are indications that mutations in such genes may influence body mass composition 19, 20, 21, 22, 23 . For example, the tumour suppressor gene ARH1 inhibits cell growth. A deletion in ARH1 is commonly associated with breast and ovarian carcinoma while mice that are engineered to overexpress ARH1 are significantly smaller than wild type counterparts 24 . Mice possessing knockouts of genes within the tumorigenic hypoxia inducible pathway vary in size and respond to high-fat diets differently from those without the mutations 25, 26 . TP53 is the most frequently mutated gene in human cancers and is a key regulator of a number of cellular activities which prevent tumorigenesis, including maintaining genomic stability, controlling cell growth and metabolism 19, 27, 28 . Mouse models of TP53 mutations have demonstrated that reduction of p53 activity can increase cancer risk, alter metabolism and influence obesity in a complex and signal dependent manner 20, 21, 22, 23 .
Further evidence for the relation between body size, genetics and cancer comes human genetic disease, such as Turner syndrome. Turner Syndrome is defined by complete or partial chromosome X monosomy and is associated with a distinct clinical phenotype, including gonadal dysgenesis, cubitus valgus and short stature 29 . Short stature within this condition has been attributed to haplo-insufficiency of the SHOX tumour suppressor gene 30 . Deletions and mutations in SHOX have also been identified as an explanation for short stature within the general population 31 . Another example comes from patients with Simson-Golabi-Behmel syndrome (SGB), caused by mutations in the GPC3 tumour suppressor gene. Patients with SGB tend to have pre-and post-natal overgrowth and thus ultimately taller stature as well as an increased risk of embryonic tumours. In line with this, GPC3-null mice also display overgrowth 32 . Effects in both humans and mice are thought to be due to unshackling of the hedgehog pathways, and increasing cellular proliferation 33, 34, 35 .
These rarer diseases provide evidence that major differences in the expression of cancer genes can influence both anthropometric traits and cancer risk in specific cohorts of patients. However, it is less clear if such associations occur in the broader population. The availability of large phenotypic and genetically linked datasets, has allowed unsupervised approaches, such as genome-wide association studies (GWAS) of common single nucleotide polymorphisms (SNPs), to be deployed to further understand the link between genetics and anthropometric traits. Pleiotropy is the phenomenon whereby a single SNP or genetic mutation can influence multiple traits. Until now, it has been difficult to look for pleiotropy between functional SNPs in genes associated with cancer risk and anthropometric traits, as very few cohorts possess both comprehensive genetic data and detailed anthropometric data in the same population. In fact, the UK Biobank provides a unique opportunity to investigate such pleotropic associations in a large prospective cohort of over 500,000 participants.
Results:
Through integration and curation of the GWAS catalog, eQTL databases and the Cancer Gene Census we identified 100 SNPs, which have been shown to associate with a differential risk of developing a total of 21 different cancer types and differential gene expression in at least one tissue type of (i) proto-oncogenes (8 genes) (ii) oncogenic fusion proteins (8) , (iii) tumour suppressors (16) and (iv) 15 genes that span two or more of these groups (supplementary tables 1 and 2). We define these SNPs as cancer eSNPs. In our analyses of the UK Biobank cohort, we found 13 cancer eSNPs associated with differences in anthropometric traits and 31 with differential cancer risk. Interestingly, 7 of these SNPs overlapped and thus displayed some level of pleiotropy between cancer risk and anthropometric traits ( Fig. 1 , supplementary tables 3&4). These 7 cancer eSNPs are found on three different chromosomes and in linkage disequilibrium (see methods) with at least one other identified cancer eSNP ( Fig. 2) . They have been found to be associated with differential expression levels of (i) Fanconi Anemia, complementation group A, FANCA [rs1805007, rs258322], (ii) tumor suppressor p53, TP53 [rs78378222, rs35850753, rs8753], and Mitogen-Activated Protein Kinase 3, Kinase 1 [MAP3K1: rs889312, rs1862626]). Both cancer eSNPs associated with FANCA expression reside in neighbouring genes; rs258322 is a non-coding variant within CDK10 and rs1805007 is a missense variant within MC1R. eSNPs associated with MAP3K1 expression are found in an intergenic region close to ZNF296 and MAP3K1 (5q11.2). In contrast, the two cancer eSNPs associated with differential TP53 expression are found in untranslated regions of the TP53 gene itself. rs78378222 is found in the 3'-UTR of TP53 and rs35850753 in is found the 5'-UTR of the d133 isoform of TP53. The third TP53 eSNP is in the 3'-UTR of the neighbouring POLR2A gene. The cancer eSNPs that showed the strongest association with anthropometric measures and cancer risk within their loci (lead cancer eSNP) were rs1805007 (FANCA, C>T, minor allele frequency in UK Biobank 36 = 0.102), rs78378222 (TP53, T>G, MAF= 0.012) and rs889312 (MAP3K1, C>A, MAF= 0.284).
In the UK Biobank cohort, the minor allele of rs1805007 (FANCA) was associated with an increased risk of melanoma (OR=1.63 [1.52-1.75], adjusted-p=2.57E -41 ) and nonmelanomatous skin cancer (OR=1.36 [1.31-1.41], adjusted-p=7.62E -63 ). The minor allele of rs78378222 (TP53) was associated with an increased risk of brain malignancy (OR= 3.12 [2.22-4.37] , adjusted p= 1.43E -12 ) and non-melanomatous skin cancer (OR= 1.46 [1.34-1.60], adjusted p= 5.20E -18 ). The minor-allele of rs889312 (MAP3K1) was associated with an increased risk of breast cancer (OR= 1.1 [1.07-1.13], adjusted p= 2.82E -11 ). Of note, as we selected these SNPs due to their noted association with differential cancer susceptibility in GWAS studies, our results provide an independent validation of these associations ( Fig. 3a ,
As regards the anthropometric measures, we identified an unexpected high level of pleiotropy and very strong association between the TP53 cancer eSNPs and three measures of height and six lean body mass, as well as basal metabolic rate with p-values as low as 7.54E -36 (Fig. 3b ). After quality control (QC) procedures, we identified 59 participants homozygous for the minor allele (increased cancer risk) of the lead TP53 eSNP (rs78378222), 9,253 heterozygous for the minor allele and 370,046 homozygous for the major allele. The minor allele carriers were on average taller, leaner and have a higher basal metabolic rate.
The associations of these anthropometric traits with the minor allele of the rs78378222 SNP were markedly more significant (up to almost 3 fold) and with greater effect sizes (up to almost 5 fold) than for the other pleiotropic eSNPs (Fig 3c, supplementary table and sitting height beta= -0.01 ± 0.001, adjusted p= 3.34E -9 ). We sought validation for these associations with standing height in the independent GIANT consortium dataset. To do so, we examined at all lead and linked SNPs for each pleiotropic eSNP in the results of the meta-analysis conducted by 37 . We were able to identify eSNPs for MAP3K1 (rs889312, rs1862626) and FANCA (rs1805007, rs258322), but none for TP53, 
Discussion:
This is the first comprehensive study providing evidence that functional common genetic variants in oncogenes and tumour suppressor genes can associate with both anthropometric traits and cancer risk in the general European population and in the same cohort. SNPs exhibiting these pleiotropic associations in our study are found in three different loci: (i) MAP3K1 (two SNPs in linkage disequilibrium), (ii) FANCA (two SNPs in linkage disequilibrium) and (iii) TP53 (three SNPs in linkage disequilibrium). Observations gained from mouse models designed to alter signalling pathways involving FANCA and TP53, suggested that such associations with anthropometric traits in humans could be possible. For example, targeted disruption of exons of the Fanconi Anemia group A (FANCA) gene in mice results in altered anthropometric traits, including growth retardation as well as differential cancer risk 38, 39 . Furthermore, mouse models of TP53 mutations have clearly demonstrated that reduction of p53 activity can result in increased cancer risk, altered metabolism and influence obesity in a complex and signal dependent manner 20, 21, 22, 23 .
The strongest associations we observed with both anthropometric traits and cancer risk are loci related to TP53. p53 is key regulator of a number of cellular activities which prevent tumorigenesis including maintaining genomic stability, controlling cell growth and metabolism 27, 28 . TP53 is the most frequently mutated gene in human cancers 19 . Moreover, in all families with similar TP53 mutations in their heritable genomes, a dramatic increase in cancer risk is observed (Li-Fraumeni Syndrome, LFS) 17, 40 . In recent studies, it has been shown that LFS patients not only have an increased risk of developing cancer but also an increased capacity for oxidative phosphorylation 41 , providing a potential link with anthropometric traits and basal metabolic rate. Furthermore, the well-tolerated anti-diabetic drug metformin, which is thought to inhibit mitochondrial complex 1, increases cancer-free survival in a mouse model of LFS and reduces proliferation in cancer cell lines 42, 43 . Metformin is now being trialled in LFS patients to hopefully provide a preventative option for these highrisk patients (ClinicalTrials.gov number: NCT01981525). Based on the potential link with oxidative phosphorylation, this intervention might also be trialled in those carrying the minor allele of the TP53 cancer eSNP (rs78378222).
The TP53 mutations found in LFS are rare in the general population 44 . However, here we show relatively frequent SNPs related to p53 affect cancer risk and anthropometric traits.
Notably, the allele of a SNP in the polyadenylation signal of p53 (rs78378222[C]) which is found in approximately 1% of populations of European descent, has been shown to impair 3'end processing of p53 mRNA, resulting in a reduction of p53 protein and an increased risk for glioma and basal cell carcinoma as well as affecting head circumference and intracranial volume 45, 46 . Here we not only validate these cancer associations in a separate cohort (nonmelanomatous skin cancer, OR= 1.46 [1.34-1.60], adjusted p= 5.20E -18 , brain malignancy, OR= 3.12 [2.23-4.37], adjusted p= 1.43E -12 ) but also show that carriers of this allele tend to be taller, leaner and have a higher basal metabolic rate (standing height, adjusted-p= 2.18E -24 , beta= 0.073 ± 0.007, whole body fat free mass, adjusted-p= 8.34E -37 , beta= 0.073 ± 0.005, basal metabolic rate, adjusted-p= 1.13E -31 , beta= 0.076 ± 0.006).
Prior to this study, the association between increased height and non-melanomatous skin cancer/brain malignancy were well established, however, mechanistic explanations were lacking 2, 47, 48 . Our study proves the concept that functional loci in well-characterised tumour suppressors and oncogenes alter both cancer risk and anthropometric traits and, of particular interest, identifies a strong, new, association between the rs78378222[C] SNP in the polyadenylation site of p53 with both increased risk for developing non-melanomatous skin cancer/brain malignancy and increased height, lean body mass and basal metabolic rate, thereby offering a novel genetic link between these anthropometric traits and cancer risk.
Methods

The UK Biobank:
The UK Biobank is a cohort of ~500,000 UK residents who volunteered to have their clinical, lifestyle, anthropometric and genetic data collected for research. Data was collected in a number of ways, including face-to-face interview, touchscreen assessment and from centralised clinical registers (e.g. the Cancer register and Death register). Participants were aged between 40-69 years at recruitment 49 
Anthropometric data:
During the baseline assessment, participants had various anthropometric traits measured directly or by bioelectrical impedance. Bioimpedance data was measured using a Tanita BC418MA body composition analyser. Participants stood barefoot on the analyser and held the metal handles. This device produced measurements of fat mass, fat-free mass and basal metabolic rate. Further information on anthropometric data collected is found here 50 .
Cancer data:
Cancer occurrences were defined by presence of a cancer international classification of diseases (ICD) code in the UK Cancer register or the UK Death register. To maximise the number of individual cancers cases, we combined ICD9 and ICD10 codes of identical cancers.
This was done by a clinician to ensure the matching was accurate, for instance malignant neoplasm of brain was defined as C71 (ICD10) and 191 (ICD9). With the goal of increasing power, when appropriate we merged ICD codes into clinically relevant groups. We ran individual cancers (combined ICD9 and ICD10 codes) and clinically relevant groups in our analysis.
Genetic data:
Blood samples were collected when participants were recruited, and DNA extracted 51 . DNA was then genotyped on either the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom array (Santa Clara, CA, USA). Imputation was based upon a merged reference panel of ~90 million biallelic variants, from the 1000 Genomes Phase 3 52 and the UK10K 53 haplotype panels. Imputation was performed using IMPUTE2 as described 54 , producing 488,295 genotyped participants.
Sample quality control:
In addition to the standard quality control, we carried out further quality control steps to ensure robustness of our analyses. We excluded individuals based on: a mismatched value between self-reported and genetic sex (data-field: 22001 and 31), level of genotype missingness of >0.05 (data-field: 22005), genetic relatedness factor with kinship coefficient of >0.0442, sex chromosome aneuploidy (data-field 22019), outliers for heterozygosity or missing rate (datafield: 22027). We selected the European population based on self-reported ethnicity (datafield: 21000) by excluding non-white ethnic background. This left a study population of 379,358 suitable genotyped individuals.
Identification of functional cancer gene SNPs:
We identified genes confirmed to be involved in carcinogenesis in the COSMIC Cancer Gene Census (release v88, 19th March 2019): the current reference record of genes containing cancer driver mutations. We then selected all SNPs annotated to these genes that have been significantly associated with differential cancer risk in genome-wide association studies in the GWAS catalog 55 . Significant associations with cancer risk were defined with a p-values of <5E -08 cut-off. Finally, we required that these SNPs were also associated with differential expression of the cancer gene in at least one expression quantitative trait loci (eQTL) database. cis-eQTL databases utilised were GTEX, NESDA/NTR and PancanQTL 56, 57, 58 .
SNP quality control:
SNP exclusions were Hardy-Weinberg equilibrium with p-value less than 1E -10 , a minor allele frequency less than 0.0001, level of missingness more than 0.05 or an imputation score less than 0.8 (as per http://www.nealelab.is/uk-biobank/).
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Analysis:
To carry out the SNP-wise analysis on all functional-CG SNPs we used SNPTEST (version 2.5.4) 59 , and employed the frequentist approach under dominant, additive and recessive inheritance models, using sex, age and genetic principal components (1-20 PCs) as covariates. Genetic PCs were included as covariates to control for hidden population structure.
We controlled the genotype uncertainty by implementing the missing data likelihood score test. Within SNPTEST, we used the frequentist approach under an additive inheritance model.
P-values of SNP-wise association were adjusted by the stringent Bonferroni correction based on number of tested traits (28 anthropometric traits, 50 cancer types) multiplied by the number of eSNPs (100). Significant associations were defined Bonferroni correction p values below the threshold of 1E -5 . adjusted-p Fig. 3 
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